The frequency of differentiated CD3
CD27
CD28
biomarker
chimeric antigen receptor T cells therapy
diffuse large B cell lymphoma
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
27
07
2022
accepted:
28
11
2022
entrez:
26
1
2023
pubmed:
27
1
2023
medline:
28
1
2023
Statut:
epublish
Résumé
Chimeric antigen receptor T (CART) cell therapy targeting the B cell specific differentiation antigen CD19 has shown clinical efficacy in a subset of relapsed/refractory (r/r) diffuse large B cell lymphoma (DLBCL) patients. Despite this heterogeneous response, blood pre-infusion biomarkers predicting responsiveness to CART cell therapy are currently understudied. Blood cell and serum markers, along with clinical data of DLBCL patients who were scheduled for CART cell therapy were evaluated to search for biomarkers predicting CART cell responsiveness. Compared to healthy controls (n=24), DLBCL patients (n=33) showed significant lymphopenia, due to low CD3 Low frequency of differentiated CD3
Sections du résumé
Background
Chimeric antigen receptor T (CART) cell therapy targeting the B cell specific differentiation antigen CD19 has shown clinical efficacy in a subset of relapsed/refractory (r/r) diffuse large B cell lymphoma (DLBCL) patients. Despite this heterogeneous response, blood pre-infusion biomarkers predicting responsiveness to CART cell therapy are currently understudied.
Methods
Blood cell and serum markers, along with clinical data of DLBCL patients who were scheduled for CART cell therapy were evaluated to search for biomarkers predicting CART cell responsiveness.
Findings
Compared to healthy controls (n=24), DLBCL patients (n=33) showed significant lymphopenia, due to low CD3
Interpretation
Low frequency of differentiated CD3
Identifiants
pubmed: 36700229
doi: 10.3389/fimmu.2022.1004703
pmc: PMC9868136
doi:
Substances chimiques
CD28 Antigens
0
Antigens, CD19
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1004703Informations de copyright
Copyright © 2023 Worel, Grabmeier-Pfistershammer, Kratzer, Schlager, Tanzmann, Rottal, Körmöczi, Porpaczy, Staber, Skrabs, Herkner, Gudipati, Huppa, Salzer, Lehner, Saxenhuber, Friedberg, Wohlfarth, Hopfinger, Rabitsch, Simonitsch-Klupp, Jäger and Pickl.
Déclaration de conflit d'intérêts
With regards to the authors’ disclosure of potential conflicts of interest we would like to indicate that WP receives honoraria from Novartis, Astra Zeneca and Roche. UJ reports honoraria and advisory roles for Novartis, BMS/Celgene, Gilead, Miltenyi. NW, PW, and GH report honoraria from Novartis, BMS/Celgene and Gilead. WR reports honoraria from BMS/Celgene. JH reports honoraria from Novartis. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Leuk Lymphoma. 2008 May;49(5):959-64
pubmed: 18464115
In Vitro Cell Dev Biol. 1986 Dec;22(12):689-94
pubmed: 3023278
Transfusion. 2017 May;57(5):1133-1141
pubmed: 28236305
J Clin Invest. 2019 Mar 21;129(6):2210-2221
pubmed: 30896447
Blood Adv. 2022 Aug 9;6(15):4657-4660
pubmed: 35728051
Blood. 2017 Oct 19;130(16):1800-1808
pubmed: 28774879
J Clin Invest. 2005 Jun;115(6):1616-26
pubmed: 15931392
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
N Engl J Med. 2006 Sep 7;355(10):1018-28
pubmed: 16908486
Blood. 2012 Mar 22;119(12):2844-53
pubmed: 22323454
J Exp Med. 1979 Aug 1;150(2):246-55
pubmed: 88499
J Immunol. 1999 Jun 1;162(11):6572-9
pubmed: 10352273
J Immunol. 2001 May 15;166(10):6144-8
pubmed: 11342634
Cancer Immunol Immunother. 2022 Jan;71(1):97-109
pubmed: 34028568
Lancet. 2020 Sep 19;396(10254):839-852
pubmed: 32888407
J Clin Oncol. 2020 Sep 20;38(27):3119-3128
pubmed: 32401634
N Engl J Med. 2018 Jul 5;379(1):64-73
pubmed: 29972754
Int J Cancer. 2019 Sep 1;145(5):1312-1324
pubmed: 30737788
Transl Cancer Res. 2016 Aug;5(Suppl 2):S221-S225
pubmed: 28824851
Blood. 2012 Jan 5;119(1):72-82
pubmed: 22031866
Nat Med. 2018 Oct;24(10):1504-1506
pubmed: 30275569
Lupus. 2011 Nov;20(13):1365-71
pubmed: 21865261
J Leukoc Biol. 2010 Jan;87(1):137-45
pubmed: 19843577
Lancet Oncol. 2019 Jan;20(1):31-42
pubmed: 30518502
Blood. 2022 Jan 27;139(4):523-537
pubmed: 35084470
Immunol Today. 1990 Jun;11(6):211-6
pubmed: 2162180
Eur J Immunol. 2001 Feb;31(2):459-66
pubmed: 11180110
Hemasphere. 2019 Mar 08;3(2):e185
pubmed: 31723824
J Clin Invest. 2016 Jun 1;126(6):2123-38
pubmed: 27111235
J Cell Physiol. 2019 May;234(5):5827-5841
pubmed: 30317583
Lancet Oncol. 2014 Aug;15(9):931-42
pubmed: 25030467
Immunity. 2001 Nov;15(5):801-12
pubmed: 11728341
Cytometry A. 2008 Nov;73(11):975-83
pubmed: 18785267
Blood Adv. 2019 Oct 8;3(19):2812-2815
pubmed: 31575532
Int Immunol. 1994 Mar;6(3):477-80
pubmed: 8186199
Biol Blood Marrow Transplant. 2014 Nov;20(11):1729-36
pubmed: 25008330
Curr Opin Immunol. 2017 Apr;45:82-88
pubmed: 28319731
Nat Commun. 2020 Jan 10;11(1):219
pubmed: 31924795
J Clin Oncol. 2017 Jun 20;35(18):2028-2036
pubmed: 28463630
Mol Ther Oncolytics. 2016 Jun 15;3:16015
pubmed: 27347557
Immunol Lett. 2005 Feb 15;97(1):19-29
pubmed: 15626472
Annu Rev Immunol. 1996;14:233-58
pubmed: 8717514
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Blood Adv. 2022 Aug 31;:
pubmed: 36044388
Nat Med. 2018 May;24(5):563-571
pubmed: 29713085
Int J Cancer. 2021 Jan 15;148(2):419-428
pubmed: 32683672
Cancer Res. 2014 Dec 1;74(23):6796-805
pubmed: 25297631
Front Immunol. 2020 Jun 17;11:1109
pubmed: 32625204
Nat Med. 2002 Apr;8(4):379-85
pubmed: 11927944
Sci Immunol. 2018 May 18;3(23):
pubmed: 29776993
J Immunol. 2007 Apr 1;178(7):4112-9
pubmed: 17371966
Clin Cancer Res. 2011 Jul 1;17(13):4550-7
pubmed: 21498393
Science. 2017 Mar 31;355(6332):1423-1427
pubmed: 28280249
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Eur J Immunol. 2019 Oct;49(10):1457-1973
pubmed: 31633216
Aging Cell. 2017 Apr;16(2):293-303
pubmed: 28026094
J Immunol. 2005 Nov 15;175(10):6489-97
pubmed: 16272303
Vaccines (Basel). 2021 Aug 15;9(8):
pubmed: 34452033
Vaccines (Basel). 2022 Feb 27;10(3):
pubmed: 35335006
J Immunol. 2013 Oct 15;191(8):4174-83
pubmed: 24026078
ACS Synth Biol. 2021 May 21;10(5):1184-1198
pubmed: 33843201
Blood Adv. 2020 Nov 24;4(22):5607-5615
pubmed: 33180899
Blood Adv. 2020 Feb 11;4(3):560-572
pubmed: 32045475
Ann Hematol. 2012 Mar;91(3):375-82
pubmed: 21811783
J Immunol. 1995 Mar 15;154(6):2612-23
pubmed: 7876536
Dev Comp Immunol. 1997 Nov-Dec;21(6):471-8
pubmed: 9463780
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Cancer Cell. 2017 Dec 11;32(6):777-791.e6
pubmed: 29198913
Cancer Immunol Res. 2015 May;3(5):473-82
pubmed: 25711538
Nat Immunol. 2000 Nov;1(5):433-40
pubmed: 11062504
J Clin Oncol. 2012 Dec 20;30(36):4462-9
pubmed: 23091101